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BACKGROUND: Variants of the desmosomal protein desmoplakin are associated with arrhythmogenic cardiomyopathy, an im-
portant cause of ventricular arrhythmias in children and young adults. Disease penetrance of desmoplakin variants is in-
complete and variant carriers may display noncardiac, dermatologic phenotypes. We describe a novel cardiac phenotype 
associated with a truncating desmoplakin variant, likely causing mechanical instability of myocardial desmosomes.
METHODS AND RESULTS: In 2 young brothers with recurrent myocarditis triggered by physical exercise, screening of 218 
cardiomyopathy- related genes identified the heterozygous truncating variant p.Arg1458Ter in desmoplakin. Screening for 
infections yielded no evidence of viral or nonviral infections. Myosin and troponin I autoantibodies were detected at high titers. 
Immunohistology failed to detect any residual DSP protein in endomyocardial biopsies, and none of the histologic criteria of 
arrhythmogenic cardiomyopathy were fulfilled. Cardiac magnetic resonance imaging revealed no features associated with 
right ventricular arrhythmogenic cardiomyopathy, but multifocal subepicardial late gadolinium enhancement was present in 
the left ventricles of both brothers. Screening of adult cardiomyopathy cohorts for truncating variants identified the rare genetic 
variants p.Gln307Ter, p.Tyr1391Ter, and p.Tyr1512Ter, suggesting that over subsequent decades critical genetic/exogenous 
modifiers drive pathogenesis from desmoplakin truncations toward different end points.
CONCLUSIONS: The described novel phenotype of familial recurrent myocarditis associated with a desmoplakin truncation in 
adolescents likely represents a serendipitously revealed subtype of arrhythmogenic cardiomyopathy. It may be caused by 
a distinctive adverse effect of the variant desmoplakin upon the mechanical stability of myocardial desmosomes. Variant 
screening is advisable to allow early detection of patients with similar phenotypes.
Key Words: arrhythmogenic cardiomyopathy ■ cardiovascular genetics ■ desmoplakin ■ genome-environment interactions ■ 
myocarditis
Arrhythmogenic cardiomyopathy (AC) is considered an autosomal dominant inherited disease linked to variants in genes encoding desmosomes or 
desmosome- related proteins. There is no single gold 
standard test for AC patients, but diagnosis is based on 
a score of major and minor criteria evaluating data from 
6 different diagnostic task force criteria.1 Characteristic 
histopathological features include fibrofatty replace-
ment of right ventricular myocardium, corresponding 
to an advanced disease stage. Importantly, inflamma-
tion of the myocardium is often observed in AC, and 
differential diagnosis of early AC from myocarditis may 
be challenging.2 The primary treatment goal is preven-
tion of sudden cardiac death. AC patients are often 
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diagnosed in adolescence or young adulthood and the 
clinical decision for implantable cardioverter- defibrillator 
implantation is a particularly challenging problem.3 Due 
to uncertainties about the molecular and cellular patho-
genesis of AC,4 there are no established strategies to 
not only prevent sudden cardiac death but to also slow 
down myocardial degeneration and progressive heart 
failure.
Genetic screening in AC has identified a host of vari-
ants5 in desmosomal or desmosome- related proteins 
(junction plakoglobin, desmoplakin, plakophilin 2, des-
moglein- 2, desmocollin- 2), sarcomeric or intermediate 
filaments (desmin, titin), and immunoregulatory pro-
teins (transforming growth factor- β3).
Here, we describe 2 brothers presenting with re-
current myocarditis associated with a desmoplakin 
truncation. These unusual cases point to genetic pre-
disposition within the myocarditis spectrum and the 
relevance of early genetic testing in myocarditis in a 
much broader sense. Moreover, we report a striking 
discrepancy between essentially complete loss of 
desmoplakin protein from the myocardium of these 
patients despite their only heterozygous desmoplakin-
defect at the genome level. It appears indispensable to 
analyze the transcript and protein level within the tis-
sue actually affected in patients, to recognize their in-
dividual pathogenesis. This is of particular importance 
since desmoplakin variant carriers may display der-
matologic phenotypes without cardiac involvement.6,7 
Haploinsufficiency of the truncated desmoplakin pro-
tein, leading to dysfunctional desmosomes, may be 
responsible for the severe familial phenotype of the 2 
brothers.
METHODS
The authors declare that all supporting data are availa-
ble within the article and its online supplementary files.
Patients and Variant Screening
The family depicted in Figure 1 was identified during 
routine clinical patient management including genetic 
testing for cardiomyopathy- related variants, to which 
all investigated family members gave informed writ-
ten consent. Screening was performed using targeted 
next- generation sequencing combined with the gold 
standard Sanger technique as described.8,9
Other patients with truncating desmoplakin vari-
ants were identified by analysis of genetic databases 
generated during a project conducted at Heidelberg 
Medical University. This project was approved by 
the university’s institutional ethics committee (S- 
390/2011) with written informed consent from each 
proband. In total, 384 cardiomyopathy patients from 
Heidelberg were tested for desmoplakin variants. 
Preparation of sequencing libraries and data anal-
ysis was done using well- established protocols for 
either panel, whole- exome, or genome sequencing, 
as published.10–12
Desmoplakin Expression in Myocardium 
and Immune Cells
Desmoplakin transcription was evaluated in left 
ventricular (LV) myocardium and blood from pa-
tients with dilated cardiomyopathy (DCM), and in 
CLINICAL PERSPECTIVE
What Is New?
• We describe a novel cardiac phenotype associ-
ated with a truncating desmoplakin variant, likely 
causing mechanical instability of desmosome-
intermediate filament complex as the primary, 
and myocarditis as a secondary phenomenon.
• Association between desmosomal protein vari-
ants and recurrent myocarditis triggered by ex-
ercise has implications for adult and pediatric 
cardiology.
• Testing of the “mechanical failure” hypothesis in 
experimental models is warranted.
What Are the Clinical Implications?
• Recurrent myocarditis should serve as a pos-
sible indicator of genetic cardiomyopathy and 
implicates state-of-the-art genetic screening, 
unless other myocarditis triggers are unequivo-
cally established.
• The association of recurrent myocarditis with 
competitive sports illustrates the need to 
consider genome-environment interactions, 
even if a pathogenic genetic variant has been 
established.
• Limitation of peaks of physical exercise may be 
highly effective before secondary pathomecha-
nisms (eg, myocardial inflammation) ensue.
Nonstandard Abbreviations and Acronyms
AC arrhythmogenic cardiomyopathy
AM acute myocarditis
DCM dilated cardiomyopathy
DIFC  desmosome-intermediate filament 
complex
EMB endomyocardial biopsy
FACS fluorescence-activated cell sorting
LV left ventricular
MRI magnetic resonance imaging
PBMC peripheral blood mononuclear cell
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fluorescence- activated cell sorting (FACS)- sorted pe-
ripheral blood mononuclear cell (PBMC) subpopula-
tions, by use of RNA sequencing as described.10–14
Cardiac Magnetic Resonance Imaging 
and Analyses
The cardiac magnetic resonance imaging (MRI)  studies 
were performed and evaluated by standard proce-
dures as described.15
Histological, Immunohistological, and 
Virological Analyses
Endomyocardial biopsies (EMBs) and PBMCs were 
investigated for the presence of intramyocardial or 
intracellular viral genomes, and desmoplakin and other 
structural myocardial proteins were detected as de-
scribed.16–19 Specifically, immunohistochemical detec-
tion of desmoplakin was performed using polyclonal 
rabbit anti- desmoplakin antibody (Novus) at 1:50 dilu-
tion, dystrophin using polyclonal rabbit anti- dystrophin 
antibody (Zytomed) at 1:70 dilution, and dysfer-
lin20–22 using polyclonal rabbit anti- dysferlin antibody 
(Invitrogen) at 1:100 dilution.
Serum Autoantibody Detection and FACS 
Analyses of PBMCs
Autoantibodies against cardiac myosin, troponin I or 
Z, were assayed as described.23–25 Specifically, serum 
blood samples were collected and antibody titers were 
Figure 1. Genetic analysis of the family.
A, Large-scale variant screening by sequencing of 218 cardiomyopathy-related genes was conducted in both brothers to identify 
a possible genetic basis of their disease. Subsequent filtering with a minor allele frequency of 0.001 revealed three variants in 
cardiomyopathy-associated genes: Dystrophin c.3970C>T (p.Arg1324Cys), Desmoplakin c.4372C>T (p.Arg1458Ter) and nexilin 
c.154G>C (p.Asp52His). The desmoplakin variant leads to truncation of the central rod domain and complete loss of the C-terminal 
plakin repeat domains of desmoplakin involved in the transmission of mechanical signals. The relevance of 2 other rare variants of 
cardiac structural proteins (nexilin, dystrophin) detected in both brothers is uncertain. B, Sanger sequencing of the desmoplakin 
variantSanger sequencing of the desmoplakin variant in patient 11, patient 12, and individuals 1 and 2.
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determined using sandwich ELISA technique.25 To 
measure the titer of anti–troponin I or anti–major his-
tocompatibility complex autoantibodies, plates were 
coated with 50 μL/well anti–troponin I antibody (pro-
duced in hybridoma cell culture) or anti–major histo-
compatibility complex antibody (GeneTex GTX20015, 
Biozol) (1 μg/mL) in coating buffer (0.1 mol/L NaHCO3; 
34 mmol/L Na2CO3; pH 9.5) and incubated overnight. 
The GTX20015 antibody is myosin α and β heavy- chain 
specific (affinity constants for human ventricular myo-
sin heavy chains—3.33×108 M−1, human atrial myosin 
heavy chains—1.48×108  M−1, human skeletal muscle 
myosin—1.06×108 M−1); 50 μL/well of human cardiac 
troponin I (3 lg/mL) or porcine major histocompatibility 
complex (Sigma) (3 μg/mL) were added to complete 
coating. Dilution series of serum samples were 1:40, 
1:80, 1:160, and 1:320. Anti- human secondary antibody 
for IgG (1:10,000 dilution, BD) was used for detection. 
Anti–troponin I antibody or immunoadsorption- eluate 
positive for major histocompatibility complex was used 
as a positive control. We determined the optical den-
sity at a wavelength of 450  nm. Antibody end point 
titer for each individual serum was calculated as the 
highest positive dilution of antibody. FACS studies of 
PBMCs (Table S1) were conducted using published 
methods13,26,27 that are generally employed for diag-
nostics and research in clinical immunology and re-
lated disciplines.
RESULTS
Two brothers were admitted to our clinics with massive 
chest pain. The younger brother (patient 12) at age 15 
was first diagnosed as having acute myocarditis with a 
massive increase in troponin T (Figure 2) and ST eleva-
tions in the inferior and lateral leads on ECG (Figure 3). 
He reported dyspnea accompanied by vomiting and 
3 days of intermittent left arm pain. During hospitali-
zation he had 2 episodes of nonsustained ventricular 
tachycardia (Figure 3A) and 1850 ventricular extrasys-
toles per 24  hours on Holter, and 3  weeks after the 
initial event his ECG showed repolarization abnormali-
ties with T- wave inversions (Figure  3B and 3C). Two 
weeks later the 17- year- old elder brother (patient 11) 
suffered a similar, although less severe, event with ST 
elevations (Figure S1) interpreted as acute myocarditis. 
There was no prior medication or recent vaccination 
in either brother, but their mother reported recurrent 
events of “chest pains” during their childhood related 
to physical exercise. Six months later the elder brother 
(patient 11) was readmitted, this time with an episode 
as severe as initially in his brother (Figure 2). Recovery 
was slow after this recurrence, and troponin T returned 
to normal after 6 months. Over a period of 16 months, 
the younger brother (patient 12) was entirely asymp-
tomatic and had resumed normal activities including 
sports. Unexpectedly, however, he suffered a second 
Figure 2. Clinical and laboratory course.
Repetitive high levels of cardiac troponin T were observed in 2 brothers (patient 11 and 12) carrying 
a truncating desmoplakin variant p.Arg1458Ter. In both patients, the initial clinical diagnosis was 
“myocarditis” on the basis of their symptoms, ECG changes, and laboratory findings. EMB indicates 
endomyocardial biopsy; and MRI,cardiac magnetic resonance imaging.
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myocarditis event with sudden massive increase of 
troponin T (Figure  2). Of note, his mother spontane-
ously remarked that before his first as well as this sec-
ond event he had performed competitive sports. Both 
brothers performed sports with frequent high- intensity 
training (American football, basketball).
Both brothers underwent echocardiographic and 
cardiac MRI on admission and during follow- up. 
Echocardiographic examinations revealed a decreased 
LV ejection fraction in patient 12 at initial diagnosis and at 
follow- up after 18 months. Results and images of initial 
and follow- up MRI investigations are shown in Figure 4 
and Table S2. Multifocal subepicardial late gadolinium 
enhancement was present in both brothers at initial and 
follow- up studies. Patient 12 showed reduced LV ejec-
tion fraction only at follow- up, while patient 11 demon-
strated normal LV function at all time points. Focal wall 
abnormalities and myocardial edema were absent, 
implicating that no acute myocarditis was present. 
Cardiac catheterization was performed in both brothers 
at initial presentation and at follow- up, and EMBs re-
vealed low- level immune cell infiltration in the absence of 
intramyocardial virus genomes (Table S3). There was no 
evidence of myocyte death supporting the Dallas criteria 
and only low- level myocardial inflammation without de-
tection of perforin- positive cytotoxic T cells.19 In addition, 
circulating blood mononuclear cell analyses, as well as 
serologic studies yielded no evidence of viral or nonviral 
infections (Table S4). Immunologic screening identified 
circulating cardiac autoantibodies against myosin (IgM) 
and troponin I (IgG and IgM) in both brothers, consistent 
with autoimmune involvement. FACS studies of PBMCs 
to identify possible immune cell defects revealed only 
mild anomalies, which were, however, essentially iden-
tical in both cases (Table S1). Both displayed relative a 
reduction of α/β and an increase of γ/δ T cells, as well a 
discrete CD4/8 T- cell inversion.
Based on the familial occurrence of a condi-
tion presenting as acute myocarditis the patients 
were referred for genetic analysis. Screening of 218 
cardiomyopathy- related genes was conducted in both 
brothers to identify a possible genetic defect. Three 
rare variants were identified in patients 11 and 12: 
dystrophin c.3970C>T, p.Arg1324Cys, desmoplakin 
Figure 3. Electrocardiographic findings.
A, Nonsustained ventricular tachycardia of patient 12 during his first day of hospitalization. B, Twelve-lead ECG of this patient on 
admission with acute chest pain and high troponin T. C, ECG at follow-up when symptoms had subsided and Ths HP had returned to 
near normal values. Ths HP indicates cardiac troponin T.
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c.4372C>T, p.Arg1458Ter, and nexilin F- actin–bind-
ing protein c.154G>C, p.Asp52His (Figure  1). The 
heterozygous variant desmoplakin p.Arg1458Ter 
was graded as likely pathogenic according to the 
American College of Medical Genetics guidelines.28 
The desmoplakin variant is reported in one individ-
ual in ClinVar (https://www.ncbi.nlm.nih.gov/clinv 
ar/), where it is classified as pathogenic for “dilated 
cardiomyopathy with woolly hair and keratoderma, 
arrhythmogenic right ventricular cardiomyopathy, 
type 8.” It occurs at low frequency (0.000003980) 
in gnomAD (https://gnomad.broad insti tute.org), and 
it is predicted to truncate approximately half of the 
protein, inducing loss of the C- terminal plakin re-
peat domains of desmoplakin that are involved in the 
mechanical signal transmission.29 The hemizygous 
missense variant dystrophin p.Arg1324Cys and the 
heterozygous variant nexilin F- actin–binding protein 
p.Asp52His were classified as variants of unknown 
significance
The detection of the desmoplakin variant also led 
us to inspect a possible cutaneous phenotype. Both 
brothers have wooly hair; their mother originates from 
a Latino ethnic background and has curly hair; and 
the father is European with straight hair. Any specific 
recognizable cutaneous phenotype such as kerato-
derma was not visible in the brothers or the parents.
Segregation analysis revealed that the heterozy-
gous desmoplakin variant p.Arg1458Ter was inherited 
from the 49- year- old mother (Figure 1), who reported 
no history or symptoms of cardiovascular or other 
diseases. Clinical examination and cardiac imaging 
including cardiac MRI showed no cardiac abnormal-
ities. Ventricular size and function were normal, and 
there was no regional akinesia or dyskinesia (Figure 
S2). The 55- year- old father (patient 1) carried none of 
these variants, had suffered a myocardial infarction 
several years ago, and had no signs of cardiomyopathy 
from medical records.
Only after this detection of the predictably truncat-
ing nonsense desmoplakin variant in both brothers, 
a number of additional histologic and immunohisto-
logic studies were conducted on their EMBs. The 
heterozygous desmoplakin variant was expected to 
result in either an abnormal truncated protein product 
or approximately 50% loss of protein from the vari-
ant allele through nonsense- mediated RNA decay. 
Unexpectedly, there was complete loss of desmo-
plakin protein in the myocardium of patients, as far 
as detectable by immunohistochemistry (Figure 5A). 
Of note, no such loss of desmoplakin was observed 
in patients with “classical” arrhythmogenic right 
ventricular cardiomyopathy, even when all other 
histologic criteria of the disease were fully evolved 
(Figure  5A). In contrast to these findings regarding 
desmoplakin protein, there were no detectable dif-
ferences in dystrophin immunoreactivity between 
p.Arg1458Ter patients or “classical” arrythmogenic 
right ventricular cardiomyopathy patients and normal 
controls (Figure  5B). Furthermore, immunostaining 
for the sarcolemmal cell surface protein dysferlin 20–22  
revealed no differences between patients and con-
trols (Figure  5C). Desmoplakin truncating variant 
p.Arg1458Ter did not affect myocardial structure as 
Figure  4. Cardiac magnetic resonance imaging studies. Late gadolinium enhancement images of cardiac magnetic 
resonance imaging (MRI) short-axis views (left to right: basal, midventricular, apical).
A, Initial and follow-up cardiac MRI of patient 11 with multifocal subepicardial late gadolinium enhancement anterior, posterior, 
and septal. Initial left ventricular ejection fraction (LVEF) was 65%, at FU 64%. B, Initial and follow-up cardiac MRI of patient 12 
with multifocal subepicardial LGE posteroseptal and lateral. Initial LVEF was 59%, at follow-up 47%. Regions of positive LGE are 
highlighted with red arrows. For further cardiac MRI data, see Table S2.
A Paent 11
Inial CMR (01-04-2017)
Follow-up CMR (04-10-2017)
B Paent 12
Inial CMR (18-05-2017)
Follow-up CMR (06-09-2017)
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Figure 5. Protein expression in endomyocardial biopsies. Immunhistochemistry detecting desmoplakin and dystrophin 
was conducted in endomyocardial biopsies of patient 11.
A, Immunodetection reveals strong desmoplakin signals in desmosomes (yellow arrows) of the control biopsy. In the biopsy of 
patient 11 almost no significant desmoplakin signal was detectable. Of note, in a right heart biopsy from a patient with “classical” 
arrhythmogenic right ventricular cardiomyopathy, normal desmoplakin expression was observed. The anti- desmoplakin antibody 
recognizes an epitope within the N- terminal part of desmoplakin. Nuclei are shown in light blue. Magnification is ×400. B, 
Immunodetection of dystrophin appears unaffected in the biopsy of patient 11 compared with the control and arrhythmogenic
right ventricular cardiomyopathy patient. C, Immunostaining for the sarcolemmal cell surface protein dysferlin revealed 
no differences between patients and controls. D and E, H&E and trichrome stainings identified no alterations of 
myocardial structure. F, MHCII staining showed low level inflammation with infiltrating macrophages (for further EMBx 
data see Table S3). H&E indicates hematoxylin and eosin; and MHCII, major histocompatibility complex class II.
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assessed by hematoxylin and eosin and trichrome 
stain (Figure 5D and 5E), and there was only low level 
inflammatory activation (Figure 5F). Interestingly, his-
tology could not detect fibrofatty replacement of right 
ventricular myocardium at biopsy.
We detected desmoplakin transcript in PBMCs 
(Figure S3), which raises the question to what extent 
desmoplakin variants affect immune functions. Of 
note, in a cohort of DCM and in control patients, we 
were able to detect desmoplakin transcripts in both 
PBMCs and left- ventricular heart tissue (Figure S3A).30 
In PBMCs from the p.Arg1458Ter carriers, desmo-
plakin transcript was likewise detected (Figure S3B). 
To our knowledge, the functions of desmoplakin in im-
munity have not been addressed so far. Unpublished 
data from a previous RNA- sequencing study on sorted 
human PBMC subpopulations13 (Figure S3C) suggest 
that desmoplakin transcription is restricted to certain 
immune cell subtypes (CD3+, CD4+, CD19+), further 
supporting the hypothesis of immune functions of DSP.
To understand the phenotypic consequences of 
truncating desmoplakin variants, we screened addi-
tional cohorts of adult cardiomyopathy patients for such 
variants. We identified the nonsense variant Gln307Ter 
in a 37- year- old woman with “classical” arrythmogenic 
right ventricular cardiomyopathy phenotype. The sis-
ter of this patient died of heart failure at the age of 
39. A 59- year- old woman with LV noncompaction 
phenotype carried the nonsense variant Tyr1391Ter. 
Here, family history was unclear; the brother proba-
bly died of coronary artery disease. In a 71- year- old 
woman with DCM phenotype, with no family history, 
the nonsense variant Tyr1512Ter was identified. These 
examples underline the phenotypic heterogeneity of 
cardiomyopathies associated with unique severe gene 
defects and indicate the critical role of modifiers (ge-
netic or exogenous) in driving pathogenesis either way.
Overall, neither of the 2 brothers fulfilled the 2010 Task 
Force Criteria for the diagnosis of arrhythmogenic car-
diomyopathy.1 Patient 12 met 1 major (identification of a 
pathogenic variant categorized as probably associated 
with AC) and 1 minor criterion (nonsustained ventricular 
tachycardia of right ventricular outflow tract configura-
tion), therefore resulting in a borderline diagnosis of AC. 
Patient 11 fulfilled only 1 major criterion (identification of 
a pathogenic variant categorized as probably associ-
ated with AC) that results in a possible diagnosis of AC.
DISCUSSION
Myocardial Inflammation in AC 
Pathogenesis
It is well established that desmoplakin variant–associ-
ated arrythmogenic right ventricular cardiomyopathy 
can present as myocarditis. An increasingly discussed 
and clinically important aspect of AC in general is its 
relationship with and differentiation from myocardi-
tis.31 Myocarditis is often used synonymously with 
virus-induced myocardial inflammation, whereas de 
facto immune cell infiltration of the myocardium is a 
common phenomenon triggered by multiple types of 
myocardial injury. These injuries range from ischemia 
to pressure or volume overload to storage diseases 
(eg, amyloidosis). It is indispensable to avoid a priori 
association of the term myocarditis with infectious 
etiology, unless a recent or current infectious trigger 
is clearly established. Otherwise, stepwise exclu-
sion of the multiple alternative causes of myocardial 
inflammation is required before a definitive diagno-
sis is made. Regarding AC pathogenesis in patients 
with monogenic defects, this is critical since essential 
pathogenic cofactors obviously exist, but their nature 
has not been clarified yet. In the current study, we 
made an extensive effort to decide whether the ob-
served recurrent phenotype in 2 brothers carrying a 
truncating desmoplakin variant might have been trig-
gered by an infectious agent. After extensive screen-
ing for intramyocardial infectious genomes, recent or 
current systemic infection with a broad spectrum of 
viral or nonviral agents, or unspecific laboratory signs 
of infection, in combination with the absence of clini-
cal signs or symptoms of infection, we had to exclude 
an infectious trigger as entirely speculative. Further, 
noninvasive and invasive (EMB) diagnostics excluded 
ischemia, pressure or volume overload, and myocar-
dial storage disorders as cofactors. In addition, FACS 
screening exluded major cellular or humoral immune 
disturbances as possible cofactors of disease patho-
genesis. In the described 2 particular cases with a 
mechanically highly relevant desmoplakin variant, all 
clinical and other findings are instead fully consistent 
with the alternative model proposed in Figure  6. To 
our knowledge, there is no prior report encompass-
ing comprehensive exclusion of intramyocardial or 
systemic infections, immune disturbances, and the 
above- mentioned possible alternative cofactors, in 
AC patients with desmoplakin variants.
Important previous studies32,33 suggested that 
previously silent recessive defects of the myocardium 
may predispose to acute heart failure presenting as 
“acute myocarditis” (AM), notably after common viral 
infections in children. While this model is of high clin-
ical interest and may be relevant in a fraction of “ge-
netically predisposed” individuals, it obviously does 
not apply to our cases. Another study investigated 
the genetic basis of AM in AC and tested for possible 
association with poorer prognosis and higher risk of 
ventricular arrhythmias.31,34 Among 131 patients with 
AC, 7 presented with a clinical diagnosis of AM, but 
this study did not screen for viral or other infectious 
genomes in EMBs, serologic or other evidence of 
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past or current infections, or immune disturbances. 
In one paper reporting desmoplakin variant–associ-
ated AC presenting as AM,35 no EMB data on viral 
or other infectious genomes, histology, or immuno-
histochemistry were presented. Assumption of an 
infectious trigger in these studies therefore remains 
speculative.
Beyond this lack of evidence of infection, the “sin-
gle event” clinical phenotype of AM in these reports is 
strikingly distinct from the “recurrent” life- threatening 
phenotype of the sibling cases described here. Of 
note, detection of “inflammation” per se by cardiac 
MRI36 or EMB has low differential diagnostic and 
thus clinical potential, since it occurs unspecifically 
in multiple etiologically unrelated types of injury. Of 
course, the cardiac MRI findings cannot be invoked 
to suggest an infectious trigger without further direct 
evidence.
“Mechanical Failure” Model
The described brothers with severe myocarditis- like 
events had episodes of massive chest pain and sig-
nificant transient troponin elevation that were remark-
ably associated with physical exercise. The lack of 
any evidence of infections or other trigger events sug-
gests that these episodes may represent early active 
phases of a pathogenic process primarily enabled by 
instability of the desmosome- intermediate filament 
complex (DIFC) attributable to the truncating defect of 
DSP, which constitutes 1 key component of the DIFC 
(Figure 6).
Important in- depth studies of myocardial desmo-
some structure down to the electron microscopic 
level37–41 have provided insight into the functions of 
desmoplakin within the desmosome and suggest a 
straightforward mechanistic hypothesis to explain 
the adverse clinical effect of the p.Arg1458Ter variant 
Figure 6. Mechanical failure hypothesis.
Ultrastructural studies of myocardial desmosomes suggest a possible consequence of haploinsufficiency due to the p.Arg1458Ter 
truncation. Desmosome- intermediate filament complex (DIFC) denotes a multiprotein complex supporting mechanical stability. 
Desmoplakin needs to forms homodimers (white arrow), and midregion coiled- coil rod domain of desmoplakin with amino acids 1057 
to 1945 (red arrows) is essential for homodimerization. Variants p.Tyr1391Ter, p.Arg1458Ter, and p.Tyr1512Ter delete major parts of 
this domain. Glc307Ter deletes the domain entirely. If normal and pathogenic variant allele were translated with ≈1:1 ratio into protein, 
the cell should harbor one- fourth normal, one- fourth pathogenic variant, and one- half mixed desmoplakin dimer, which is likely to 
significantly impair coiled- coil domain- dependent mechanical function within the DIFC. Loss of the C- terminal “head” of desmoplakin 
(yellow arrow) that is involved in mechanical signal transmission may further impair mechanical robustness of the heart. LV indicates 
left ventricular; and RV, right ventricular.
Normal
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Mechanical stress
Deleterious effect of DSP trunca via destabiliza of desmosome intermediate filament complex (DIFC)
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muta ns
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(hypothesis, Figure 6). Desmoplakin haploinsufficiency 
may lead to dysfunctional desmosomes with loss of 
numerous proteins from the DIFC.42–44 Whereas gap 
junctions allow electrical coupling between cardio-
myocytes, desmosomes are junctions that link to the 
intermediate filament cytoskeleton, thus providing 
mechanical strength to the myocardium.37 Regarding 
factors that trigger the disease, our cases suggest 
that mechanical overload per se may suffice to elicit 
disease. Troponin peaks above 5.000 ng/mL in both 
cases dropped rapidly after the acute events. This is 
consistent with high- level physical activity as trigger 
events and reminiscent of the peaklike elevations of 
troponin upon fulminant pulmonary embolism resulting 
in acute mechanical overload.45
Of note, any dimeric protein component of the 
DIFC could in principle exert a similar adverse effect 
upon DIFC function if the encoding gene carries a 
truncating variant as exemplified by desmoplakin. 
We suggest that the described phenotype of famil-
ial recurrent myocarditis represents a serendipitously 
revealed molecular subtype of AC, primarily triggered 
by distinctive adverse effect of the trunctated DSP 
upon the mechanical stability of myocardial desmo-
somes. Subsequent secondary events would include 
“unspecific” activation of innate and adaptive im-
munity and determine the long- term clinical course 
dependent on exogenous and epigenetic cofactors 
(Figure 6).
Primary Versus Secondary Pathogenic 
Factors
In our report, the detection of high- titer autoantibody 
against cardiac myosin and troponin I23,24 is consistent 
with disturbed autoimmune control as a contributing 
factor aggravating a primarily mechanical defect. While 
this justifies the term autoimmune myocarditis, recur-
rent massive bouts of troponin release cannot be linked 
to stably elevated autoantibody titers. Thus, mechani-
cal instability of the DIFC appears as the primary, and 
autoantibody formation as a secondary phenomenon.
One may speculate that the anomalous truncated 
desmoplakin protein may have initiated this distur-
bance, thus not only acting directly by its dysfunction-
ality, but also as an innate immunity trigger. In fact, 
desmoplakin protein is targeted in a number of der-
matologic autoimmune diseases.46 Desmoplakin auto-
antibodies may bind to the surface of keratinocytes, 
become internalized via plasmalemmal vesicles, and 
may then be found within cutaneous desmosomal 
plaques, providing a possible mechanism for how the 
autoantibodies exert pathogenic effects. Similar pro-
cesses may occur in the myocardium when patho-
genic variant desmoplakin becomes exposed to the 
immune system.
Variable Phenotypic Expression of 
Desmoplakin Variants
Disease mechanisms vary according to the specific 
types of desmoplakin variant and include haploinsuf-
ficiency, dominant negative effects, or a combination 
of both.47 In the cases reported here, definitive resolu-
tion of the molecular pathomechanism cannot possibly 
be achieved because of lack of sufficient myocardial 
biopsy material. Of note, the biopsy- based myocardial 
findings in the affected brothers yield information about 
a far earlier and therefore clinically more relevant phase 
of the disease process than what can be learned from 
postmortem hearts, which often are the sole source 
of information in genetic cardiomyopathies. As des-
mosomal proteins are expressed in myocardium and 
epidermis, AC and DCM are occasionally associ-
ated with cutaneous manifestations like palmoplantar 
keratoderma and woolly hair.47 The protein exists in 2 
isoforms, DSP1 and DSP2, produced by alternative 
splicing, and DSP1 is the only isoform expressed in 
the myocardium, whereas both DSP1 and DSP2 are 
expressed in the epidermis. The variant p.Arg1458Ter 
is located in DSP1, leading to premature truncation af-
fecting the DSP1 isoform only. Our study also shows, 
for the first time, desmoplakin transcription restricted 
to immune cell subtypes CD3+, CD4+, and CD19+, sug-
gesting unknown immune functions of desmoplakin, 
which warrant further investigation.
The truncating variants Gln307Ter, Tyr1391Ter, and 
Tyr1512Ter were detected in adult cardiomyopathy 
patients at 37, 59, and 71 years of age, respectively. 
In these patients, variant- dependent myocardial path-
omechanisms had 2 to 5 decades more to evolve. 
Therefore, their divergent clinical phenotypes—at 
time of diagnosis—may well be a consequence of 
decades of disease- modifying exogenous or genetic 
background factors driving pathogenesis into different 
directions. In the young brothers, relevance of their het-
erozygosity for the rare variant p.Asp52His in the nex-
ilin F- actin–binding protein is uncertain in that regard 
(Figure S4). Of note, however, nexilin F- actin–binding 
protein knockout in mice leads to severe cardiomyop-
athy and endomyocardial fibroelastosis.47 Further, nex-
ilin F- actin–binding protein was identified as causative 
and as a modifier gene of DCM,48,49 and a new com-
ponent of junctional membrane complexes required for 
cardiac T- tubule formation.50–52
The course of AC is influenced by sex hormones, 
with elevated serum testosterone levels in men and de-
creased estradiol levels in women independently as-
sociated with major adverse cardiovascular events.53 
Among patients with sporadic AC, men had a signifi-
cantly higher risk of ventricular tachycardia/ventricular 
fibrillation, whereas women had a significantly higher 
risk of heart failure death or heart transplantation 
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attributable to heart failure.54 Pediatric patients dispro-
portionately presented with sudden cardiac death.55 
Of note, our patients’ mother carried the desmoplakin 
variant but was clinically unaffected, possibly because 
of the known protective influence of female sex.
Implications for the Clinical Care of 
Patients at Risk
Earliest possible recognition of patients at genetic risk 
is of critical importance, since in these individuals the 
identification and avoidance of exogenous triggers 
may allow survival for decades. Since duplicate recur-
rent myocarditis in 1 family is a most unusual situation, 
variant screening even in isolated cases of “myocardi-
tis” seems advisable to enable early genetic risk de-
tection and preventive measures in these often young 
patients. The bouts of “chest pain” in our cases during 
their childhood, as reported by their mother, may reflect 
earlier similar events that went undiagnosed because 
of their unsuspicious nature.55–57 Whereas inhibition of 
pathogenic variant desmoplakin expression is not yet 
clinically feasible58 and there is no pharmacologic ap-
proach to compensate for desmoplakin deficiency,59 
limitation of physical exercise may be highly effective if 
initiated early enough before secondary pathomecha-
nisms (eg, myocardial inflammation) ensue. Both broth-
ers carry event recorders, so far without detection of 
critical arrhythmias, so that in view of their currently 
normal cardiac function, there is no indication for im-
plantable cardioverter- defibrillator implantation.
STUDY LIMITATIONS
After extensive exclusion of alternative disease trigger 
factors, the proposed mechanical failure model is fully 
consistent with state- of- the- art basic research and 
clinical knowledge. Limited availability of patient myo-
cardial tissue for in- depth ultrastructural and ex vivo 
functional studies in variant carriers prevents, however, 
direct proof of the model. Since any defective dimeric 
protein component of the DIFC could exert a similarly 
strong effect upon mechanical DIFC function as the 
desmoplakin pathogenic variant reported here, further 
testing of the mechanical failure hypothesis in experi-
mental models appears warranted.
CONCLUSIONS
The described novel phenotype of familial recurrent 
myocarditis associated with a desmoplakin truncation 
likely represents a serendipitously revealed subtype of 
AC. After comprehensive exclusion of alternative known 
trigger factors, and considering recent ultrastructural 
knowledge on desmoplakin functions, this peculiar 
phenotype may be triggered by a distinct adverse of 
the variant desmoplakin upon the mechanical stability 
of myocardial desmosomes. Variant screening is ad-
visable to allow early detection of patients with a similar 
phenotype, to possibly enable prophylactic measures 
targeting this type of pathomechanism.
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Table S1 
 
Immunological studies  
 
RNA sequencing analysis of normal human PBMCs  
Values are given as RPKM 
Transcript CD3+ CD4+ CD8+ T-reg CD19+ CD14+ CD56+ 
DSP 0,013 0,010 0,000 0,000 0,086 0,000 0,000 
 
 
FACS analyses on PBMCs from DSP mutation carrier  
 
Parameter Unit Value Reference range 
B Cells    
naive B cells /nl 0.247  
naive B cells % 82.7 63.3-88.0 
marginal zone-like B cells /nl 0.015  
marginal zone-like B cells % 5.2 P ↓ 6.1-16.9 
IgM only memory B cells /nl 0.002  
IgM only memory B cells % 0.7  
switched memory B cells /nl 0.012  
switched memory B cells % 4.0 P ↓ 4.1-18.7 
transitional B cells /nl 0.010  
transitional B cells % 3.2 0.6-3.4 
CD21low CD38low B cells /nl 0.005  
CD21low CD38low B cells % 1.7 0.9-7.6 
switched plasmablasts /nl 0.004  
switched plasmablasts % 1.3 0.4-3.6 
CD19+ B cells /nl 0.30 0.10-0.40 
NK Cells    
NK cells /nl 0.25 0.10-0.40 
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NK cells, % of lymphocytes % 9 5-25 
Naive CD45RA+, % of CD4+ % 66  
T Cells    
memory CD45RO+, % of CD4+ % 34  
naive CD45RA+, % of CD8+ % 67  
memory CD45RO+, % of CD8+ % 33  
γ/δ TCR+ T cells, relative % 22 P ↑ < 10 
α/β TCR+ T cells, relative % 78 P ↓ > 90 
γ/δ TCR+ T cells /nl 0.50  
α/β TCR+ T cells /nl 1.80  
TCRαβ+ CD4- CD8-, % of TCRαβ+ CD3+ % 1.40 < 2.00 
CD19+ B cells, % of lymphocytes % 10 5-25 
CD4/CD8 ratio  0.5 P ↓ 1.1-3.0 
CD8- CD4- T cells, % of T cells % 17.30 P ↑ < 15.00 
CD8+ CD4+ T cells, % of T cells % 0.61 < 10.00 
CD3+ T cells /nl 2.30 0.80-3.50 
CD3+ T cells, % of lymphocytes % 81 60-85 
CD4+ T cells /nl 0.65 0.50-1.20 
CD4+ T cells, % of lymphocytes % 23 P ↓ 30-60 
CD4+ % T cells % 28.19  
CD8+ T cells /nl 1.24 P ↑ 0.30-0.80 
CD8+ T cells, % of lymphocytes % 43 20-40 
CD8+ % T cells % 53.89  
Lymphocyte proliferation/function    
PHA, patient cpm 54479  
PHA, healthy control  cpm 31723  
IL-2, patient cpm 5795  
IL-2, healthy control cpm 6015  
anti-CD3, patient cpm 19591  
anti-CD3, healthy control cpm 5833  
PWM, patient cpm 4831  
PWM, healthy control cpm 5482  
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SAC, patient cpm 1096  
SAC, healthy control cpm 2003  
Tetanus, patient cpm 810  
Tetanus, healthy control cpm 94  
Candida, patient cpm 1763  
Candida, healthy control cpm 339  
Diphtherie, patient cpm 30  
Diphtherie, healthy control cpm 31  
Medium, patient cpm 31  
Medium, healthy control cpm 25  
Tetanus SI, patient  26.1 > 3.0 
Tetanus SI, healthy control  3.8 > 3.0 
Candida SI, patient  56.9 > 3.0 
Candida SI, healthy control  13.6 > 3.0 
Diphtherie SI, patient  1.0 P- > 3.0 
Diphtherie SI, healthy control  1.2 P- > 3.0 
PHA SI, patient  1027.9 > 50.0 
PHA SI, healthy control  991.3 > 50.0 
IL-2 SI, patient  109.3 > 30.0 
IL-2 SI, healthy control  188.0 > 30.0 
Anti-CD3 SI, patient  369.6 > 30.0 
Anti-CD3 SI, healthy control  182.3 > 30.0 
PWM SI, patient  91.2 > 20.0 
PWM SI, healthy control  171.3 > 20.0 
SAC SI, patient  20.7 > 10.0 
SAC SI, healthy control  62.6 > 10.0 
Medium, patient cpm 53  
Medium, healthy control cpm 32  
 
CD8+ lymphocytosis, relative reduction of CD4+ cells, decreased CD4+/CD8+ ratio; increase of 
γδ T cells vs. αβ T cells; reduced switched mature B cells, delayed B cell maturation. 
Normal  absolute numbers of CD4+ cells, T cells, B cells, NK cells, monocytes, and granulocytes; 
normal fraction of CD45RA+ CCR7+ naive T cells; lymphocytes display normal proliferation 
reactions towards 2/3 recall antigens and alltested T and B cell mitogens compared to a healthy 
control subject, and no evidence for defective signaling. 
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Serum autoantibody screening of DSP mutation carrier  
 
Parameter Unit Value Reference range 
anti-myosin_IgM titer 1:160 < 1:40 
anti-myosin_IgG titer negative < 1:40 
anti-troponin I_IgM titer 1:80 < 1:40 
anti-troponin I_IgG titer 1:40 < 1:40 
antinuclear Ab (ANA)/HEp-2-IF titer negative < 1:160 
anti-ds-DNA-Ab/Crithidien-IF titer negative < 1:10 
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Table S2 
Cardiac magnetic resonance imaging (CMR) of brothers heterozygous for DSP truncating mutation Arg1458Ter 
 
 Patient 12 Patient 11 
Date 01-04-2017 04-10-2017 18-05-2017 06-09-2017 
LV-EF (%) 59 47 65 64 
LV-EDV (ml/m2) 103 (62-102) 104 (62-102) 88 (82-113) 120 (82-113) 
LV-ESV (ml/m2) 42 (18-39) 57 (18-39) 29 (9-41) 44 (9-41) 
LV myocardial mass 
(g/m2) 83 (42-98) 73 (42-98) NA 88 (45-81) 
T2 (Edema) normal 1,6/1,5 (<2,0) 
normal 
1,8/1,9 (<2,0) 
borderline 
2,0/2,2 (<2,0) 
borderline 
2,2/1,8 (<2,0) 
Early enhancement 2,8/5,2/5,0 (<5,0) <5,0 2,9/2,0/3,7 (<5,0) 0,8/0,0 (< 5,0) 
Late gadolinium 
enhancement 
subepicardial basal & 
apical 
subepicardial 
postero-septal & 
lateral 
subepicardial 
anterior, posterior & 
septal 
subepicardial 
anterior, posterior & 
septal 
LVEDD (mm) 53 normal 
57 
enlarged  
53 
normal 
58 
enlarged 
Dyskinesia none postero-septal none NA 
Focal wall 
abnormalities none none none none 
EDV = enddiastolic volume; EF = ejection fraction;  ESV = endsystolic volume; LV = left ventricle; LVEDD = left ventricular 
enddiastolic diameter 
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Table S3 
Results of endomyocardial biopsies (EMB) of brothers heterozygous for DSP truncating mutation Arg1458Ter 
  Patient 12 Patient 11 
Date  30-03-2017 22-05-2017 20-09-2017 
Location  RV RV RV 
Fibrosis  None Moderate interstitial Moderate interstitial 
Myocyte necrosis  None None None 
Immunhistochemistry 
     CD3 
     CD68/MHC II 
 
 
Elevated 
None 
 
Slightly elevated 
Slightly elevated 
 
Normal 
Moderately elevated 
Myocardial viral § or 
other infectious $ 
genomes  
 
None None None 
 
RV = right ventricle 
 
§ parvovirus B19 (PVB19), enteroviruses (EV), human herpesviruses (HHV6/7), Epstein-Barr virus (EBV), adenoviruses 
(AdV2/5), human cytomegalovirus (CMV), herpes simplex viruses (HSV1/2), varicella zoster virus (VZV), mumps virus  
 
$ Toxoplasma gondii, Borrelia burgdorferi 
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Table S4 
 
Screening of DSP mutation carriers for systemic or intramyocardial infections  
 
Serum antibodies   
Enterovirus group (EV) IgG ∅ IgA ∅ 
Adenovirus group (AdV) IgG + IgM ∅ 
Human herpesvirus 6 (HHV6) IgG + IgM ∅ 
Herpes simplex virus types 1/2 (HSV1/2) IgG + IgM ∅ 
Parvovirus B19 (PVB19) IgG ∅ IgM ∅ 
Varicella zoster virus (VZV) IgG + IgM ∅ 
Human Cytomegalovirus (HCMV) IgG ∅ IgM ∅ 
Epstein-Barr virus (EBV) EBNA1, VCA IgG ∅  IgM ∅ 
Borrelia burgdorferi IgG ∅ IgM ∅ 
Chlamydia pneumoniae IgG ∅ IgM ∅ 
Mycoplasma pneumoniae IgG + IgM ∅ 
Haemophilus influenzae IgG + 4.48 IE  
   
Viral genomes in sputum   
Influenza A virus (H1, H3, H1N1) Multiplex PCR ∅  
Influenza B virus Multiplex PCR ∅  
Respiratory syncytial virus (RSV) types A/B Multiplex PCR ∅  
Coronavirus (HKU1, NL63, OC43) Multiplex PCR ∅  
Parainfluenza virus types 1-4 Multiplex PCR ∅  
   
Nested PCRs on patient PBMCs   
Enteroviridae (RNA)   
Coxsackie group A/B viruses  nPCR ∅  
Echoviruses nPCR ∅  
Herpesviridae (dsDNA)   
Herpes simplex virus types 1(2 (HSV1/2) nPCR ∅  
Human herpesvirus type 6/7 (HHV6/7) nPCR ∅  
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Epstein-Barr virus (EBV) nPCR ∅  
Cytomegalovirus (HCMV) nPCR ∅  
Varizella zoster virus (VZV) nPCR ∅  
Adenoviridae (dsDNA)   
Adenovirus group (AdV) nPCR ∅  
Parvoviridae (ssDNA)   
Parvovirus B19 (PVB19) nPCR ∅  
Non-viral infectious agents   
Chlamydia pneumonia nPCR ∅  
Toxoplasma gondii nPCR ∅  
Borrelia burgdorferi nPCR ∅  
Eubacteria nPCR ∅  
   
Nested PCR on patient  EMBs   
Enteroviridae (RNA)   
Coxsackie group A/B viruses nPCR ∅  
Echoviruses nPCR ∅  
Herpesviridae (dsDNA)   
Herpes simplex virus types 1/2 (HSV1/2) nPCR ∅  
Human herpesvirus type 6 (HHV6) nPCR ∅  
Epstein-Barr virus (EBV) nPCR ∅  
Cytomegalovirus (HCMV) nPCR ∅  
Adenoviridae (dsDNA)   
Adenovirus group (AdV) nPCR ∅  
Parvoviridae (ssDNA)   
Parvovirus B19 (PVB19) nPCR ∅  
Non-viral infectious agents   
Chlamydia pneumonia nPCR ∅  
Toxoplasma gondii nPCR ∅  
Borrelia burgdorferi nPCR ∅  
Eubacteria nPCR ∅  
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Fig. S1
ECG of patient 11 at admission; 2017-05-15
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Figure S2. Echocardiography and cardiac MRI (cMRI) of the mother, patient 2, suffering 
from recurrent myocarditis.  
 
 
Upper panel from left to right, enddiastolic: echocardiographic 4-chamber view, cMRI 4-chamber 
view and 2- chamber view. Lower panel from left to right, end-systolic: echocardiographic 4-
chamber view, cMRI 4-chamber view and 2- chamber view. Both children and her mother, who 
has not reported any clinical symptoms or signs resembling those of her sons, or suggesting 
heart failure or arrhythmias, carry the Arg1458Ter mutation of desmoplakin (DSP). 
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Figure S3. DSP expression in myocardium and PBMCs of patients and controls.  
 
 
 
A The expression of DSP transcripts was tested in left ventricular myocardium and blood from 
patients with dilated cardiomyopathy (DCM) with RNAseq. DSP is highly expressed in heart tissue. 
In blood DSP was detected at low levels. No difference could be detected between DCM patients 
and controls. B In PBMCs derived from patient 11 DSP transcripts were detected by PCR. (lane 
1: size marker, 100 bp ladder; lanes 2/3: cDNA from PBMCs of patient 11; lane 4: cDNA from PC3 
cells; lane 5: cDNA from 293T cells; lane 6: negative control). C RNAseq analysis of sorted human 
PBMC subpopulations suggests that DSP transcripts are restricted to immune cell subtypes CD3+, 
CD4+ and CD19+.  
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Figure S4. Heterozygous variant NEXN p.Asp52His.  
 
 
The nonsynonymous variant NEXN c.154G>C, p.Asp52His was classified as variant of unknown 
significance (VUS). It is present in both brothers and their mother. 
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